Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
Eisai revenue is slated to drop following key products patent expiry i.e. Aricept and Aciphex (Pt. exp in Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval, Eisai has three late stage candidates E-2007/ perampanel, E7080/ lenvatinib and MORAb-003/ farletuzumab. However none of these will have enough potential to nullify the loss of Aricept and Aciphex even in their best case scenario.
COMPANIES MENTIONED
Eisai
Eisai
